- A study by the National Institutes of Health found that a J & J shot followed by one of the mRNA vaccines as a booster gave a stronger immune response than a double dose of J & J.
- In response to the study, Johnson & Johnson noted that boost immunization of the vaccine increased the immune response regardless of the person’s previous primary vaccination.
- The FDA’s Vaccine and Related Biopharmaceutical Advisory Board will meet on Thursday to discuss the Moderna booster and Friday to discuss the J & J booster.
According to a National Institutes of Health study posted Wednesday, the best booster for the Johnson & Johnson COVID-19 vaccine could be either Pfizer-BioNTech or Moderna.
“Mix and Match was a big study people have been waiting for and provided a lot of new data. So far, there was nothing about Johnson & Johnson with mRNA boosters,” said Eric, Vice President of Research. Dr. Topol said. A national expert on the use of data in medical research at Scripps Research in La Jolla, California.
The study, which involved nearly 500 people, found that J & J shots followed by one of the mRNA vaccines as a booster provided a stronger immune response than two J & Js.
For those who obtained either the Pfizer or Moderna two-dose series, a booster dose of either mRNA vaccine was effective.
The new study was conducted just one day before the Advisory Board of the Important Food and Drug Administration began a meeting to discuss the possibility of booster vaccinations with Moderna and J & J vaccines. Pfizer Booster was approved on September 24th.
Stay connected: Subscribe to Coronavirus Watch. This is all the latest information about COVID-19 in the United States.
According to the agenda of the meeting, data from the NIH study will be presented to the FDA committee on Friday afternoon. We will then vote for the possibility of J & J booster shots for those who have already received the same type of shots.
This study by the Mix and Match team was sponsored by the National Institutes of Health. It compared all possible combinations of the three vaccines followed by booster immunization.
“If you look at the mix-and-match data, you’ll say,’Wow, I really want an mRNA booster.’ It basically transforms Johnson & Johnson into something as good as the mRNA two-shot series,” Topol said. Said.
Research volunteers were divided into three groups. I got one Pfizer vaccine double-dose series, one Modana double-dose series, and the other a “one-time” J & J vaccine.
Then I divided each group into three smaller groups. One acquired Pfizer as a booster, one acquired Moderna, and the other acquired J & J.
Participant antibody levels to COVID-19 were measured 2 and 4 weeks after receiving the booster shot.
Anyone who obtained either the Pfizer or Moderna series and either Pfizer or Moderna as a booster received similar protection.
The lowest antibody levels were for those who received J & J boosters following J & J shots.
“Naked in the world of COVID”:Some J & J vaccinated people feel unprotected against Delta and want mRNA shots
In response to the study, Johnson & Johnson noted that boost immunization of the vaccine increased the immune response regardless of the person’s previous primary vaccination.
“Johnson & Johnson will continue to share available boosting data with the US Food and Drug Administration (FDA) and other regulatory agencies for the latest data available at this week’s Vaccine and Related Bioproducts Advisory Board. I’m looking forward to discussing it. Release.
The NIH study did not include actual data on how effective vaccines and boosters were in preventing mild or severe COVID-19. However, antibody response is considered to be an excellent indicator of vaccine efficacy.
There are somewhat comparable real-world data from Spain and the United Kingdom. Those who received a similar AstraZeneca or J & J vaccine and then the Pfizer booster had high levels of antibodies.
FDA Committee meets Thursday and Friday at Moderna, J & J Booster
The FDA’s Vaccine and Related Biopharmaceutical Advisory Board will meet on Thursday to discuss the Moderna booster and Friday to discuss the J & J booster.
The briefing document posted on Wednesday presented only data from a small survey of 17 people who took J & J booster shots six months after the first shot.
J & J is doing much more extensive research on the work, but the data has not been provided to the FDA and the FDA has decided whether to allow boosters. It’s not clear if a small group of recipients is enough for the agency to approve the 6-month booster.
Tracking COVID-19 vaccine distribution by state:How many people are vaccinated in the United States?
“We wanted to solve these problems and J & J get an emergency use authorization for the booster. Now things are a little more complicated,” said William, National Institute of Infectious Diseases Medical Director.・ Dr. Schaffner said.
Safety data for people receiving J & J boosters are good, and according to the FDA, the vaccine “provides protection against severe COVID-19 illness and death,” but is a Pfizer-BioNTech and Modern RNA-based vaccine. Not so much.
J & J said in a briefing document that boosters could be given somewhere two to six months after the first shot. This depends on who took the shot and how strong the immune response is.
Approximately 15 million Americans are fully vaccinated with the J & J vaccine, compared to 103 million who have acquired Pfizer and 69 million who have acquired Moderna. To date, 8.8 million Americans have been boosted with the Pfizer vaccine.
COVID-19 vaccine research shows that Pfizer, Moderna is J & J’s best booster
Source link COVID-19 vaccine research shows that Pfizer, Moderna is J & J’s best booster